Mrna vaccine vial closeup

The mRNA vaccine vial, a symbol of one of the 21st century's greatest scientific achievements, revolutionized immunization against COVID-19.

About this subject

mRNA vaccines represent an innovative platform that instructs cells to produce a specific pathogen protein, triggering an immune response. Unlike traditional vaccines using attenuated or inactivated viruses, mRNA vaccines contain no infectious genetic material. They consist of messenger RNA molecules encapsulated in lipid nanoparticles, which protect the RNA and facilitate cell entry. This technology enables rapid and flexible development, adaptable to emerging variants.

The historical milestone occurred in December 2020, when Pfizer-BioNTech and Moderna vaccines received emergency authorization in many countries. Clinical trials showed over 90% efficacy against symptomatic COVID-19. Success spurred billions in investment and accelerated global production. By 2023, over 13 billion doses had been administered worldwide, saving millions of lives. Logistics required ultra-cold storage, such as -70°C for the Pfizer vaccine, challenging health systems.

Beyond the pandemic, mRNA technology paves the way for vaccines against influenza, Zika, rabies, and even cancer. Ongoing clinical trials evaluate personalized tumor therapies. The platform's flexibility allows rapid response to new viral threats. However, challenges include mRNA stability, rare adverse reactions, and inequitable access between wealthy and poor countries. Continued development promises to revolutionize preventive medicine in the coming decades.

Frequently Asked Questions

How does an mRNA vaccine work?

The mRNA vaccine carries genetic instructions to produce the coronavirus spike protein. Once injected, cells use these instructions to make the protein, which is then recognized by the immune system, generating antibodies and memory cells.

Which are the main approved mRNA vaccines?

The main ones are Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna), both approved for COVID-19 in over 100 countries. Studies show high efficacy and safety, with side effects generally mild and temporary.

Can mRNA technology be used for other diseases?

Yes, the mRNA platform is promising for vaccines against influenza, Zika, HIV, rabies, and even cancer. Ongoing clinical trials evaluate its therapeutic potential, with encouraging early results in tumor immunotherapy.